Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies

References

• CDC surveillance summaries: morbidity and mortality weekly report. 51, 372–374 (2002).
   Google Scholar
• Grossman JM. In: Dubois’ Lupus Erythematosus, Sixth Edition. Wallace DJ and Hahn BH (Eds.), Lippincott, Williams & Wilkins, PA, USA, 20–31 (2002).
   Google Scholar
• Sergent JS, Lockshin MD, Klemperer MS, Lipsky BA. Central nervous system disease in SLE: therapy and prognosis. Am. J. Med. 58, 644–654 (1975).
   PubMed Web of Science ®Google Scholar
• Sibley JT, Olszynski WP, Decoteau WE, Sundram MB. The incidence and prognosis of central nervous system in SLE. J. Rheumatol. 19, 47–52 (1992).
   PubMed Web of Science ®Google Scholar
• Cook RJ, Gladman DD, Pericak D, Urowitz MB. Prediction of short-term mortality in systemic lupus erythematosus with time dependent measures of disease activity. J. Rheumatol. 27, 1892–1895 (2000).
   PubMed Web of Science ®Google Scholar
• Neuwelt CM, Lacks S, Kaye BR et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am. J. Med. 98, 32–41 (1995).
   PubMed Web of Science ®Google Scholar
• National Hospital Discharge Survey: 2000 annual summary with detailed diagnosis and procedure data. Conducted by the National Center for Health Statistics, Center for Disease Control and Prevention, Department of Health and Human Services (2002).
   Google Scholar
• Isenberg DA, Raviragan CT, Rahman A, Kalsi JK. The role of antibodies to DNA in systemic lupus erythematosus. Lupus 6, 290–302 (1997).
   PubMed Web of Science ®Google Scholar
• Okamura M, Kanayama Y, Amastu K et al. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann. Rheum. Dis. 52, 14–20 (1993).
   PubMed Web of Science ®Google Scholar
• Rahman A. Autoantibodies, lupus and the science of sabotage. Rheumatology (Oxford) 43, 1326–1336 (2004).
   PubMed Web of Science ®Google Scholar
• Forger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of antidsDNA antibodies as a prognostic marker for lupus nephritis. Lupus13(1), 36–44 (2004).
   PubMed Web of Science ®Google Scholar
• ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in antidouble-stranded DNA antibody levels as a major predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 33, 634–643 (1990).
   PubMed Web of Science ®Google Scholar
• Swaak AJ, Groenwald J, Bronsveld W. Predictive value of complement profiles and antidsDNA in systemic lupus erythematosus. Ann. Rheum. Dis. 45, 359–366 (1986).
   PubMed Web of Science ®Google Scholar
• Bootsma H, Spronk P, Derksen R et al. Prevention of relapses in systemic lupus erythematosus. Lancet 354, 1595–1599 (1995).
   Google Scholar
• Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann. Rheum. Dis. 62, 534–539 (2003).
   PubMed Web of Science ®Google Scholar
• Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum. 44, 2342–2349 (2001).
   PubMed Web of Science ®Google Scholar
• Linnik M, Hu J, Heilbrunn K, Strand V, Hurley F, Joh T. Relationship between antidsDNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 52(4), 1129–1137 (2005).
   PubMed Web of Science ®Google Scholar
• Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum. 39, 2035–2045 (1997).
   Google Scholar
• Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford) 43(12), 1555–1560 (2004).
   PubMed Web of Science ®Google Scholar
• DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus antiDNA antibodies cross-react with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Med. 7(11), 1189–1193 (2001).
   PubMed Web of Science ®Google Scholar
• Kowal C, DeGiorgio LA, Nakaoka T et al. Cognition and immunity; antibody impairs memory. Immunity 21(2), 179–188 (2004).
   PubMed Web of Science ®Google Scholar
• Coutts SM, Plunkett ML, Iverson GM, Barstad PA, Berner CM. Pharmacological intervention in antibody mediated disease. Lupus 5, 158–159 (1996).
   PubMed Web of Science ®Google Scholar
• Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J. Rheumatol. 24, 314–338 (1997).
   PubMed Web of Science ®Google Scholar
• Furie RA, Cash JM, Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 394. J. Rheumatol. 28, 257–265 (2001).
   PubMed Web of Science ®Google Scholar
• Sem DS, McNeeley PA, Linnik MD. Antibody affinities and relative titers in polyclonal populations: surface plasmon resonance analysis of antiDNA antibodies. Arch. Biochem. Biophys. 372, 62–68 (1999).
   PubMed Web of Science ®Google Scholar
• McNeeley PA, Iverson GM, Furier RA et al. Pre-treatment affinity for LJP 394 influences pharmacodynamic response in lupus patients. Lupus 10, 526–532 (2001).
   PubMed Web of Science ®Google Scholar
• Abetimus: abetimus sodium, LJP 394. BioDrugs 17(3), 212–215 (2003).
   Google Scholar
• Alarcon-Segovia D, Tumlin J, Furier RA et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 48, 442–454 (2003).
   PubMed Web of Science ®Google Scholar
• Cardiel MH, Tumlin JA, Furie RA et al. Clinical efficacy results from a randomized controlled trial (RCT) of LJP 394 in SLE patients with a history of renal disease. Arthritis Rheum. 48, S582 (2003).
   PubMedGoogle Scholar
• Wallace DJ, Tumlin JA. LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus 13(5), 323–327 (2004).
   PubMed Web of Science ®Google Scholar
• Alarcón GS, McGwin G Jr, Uribe A et al. Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum. 51, 465–474 (2004).
   PubMed Web of Science ®Google Scholar
• UrowitzMB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J. Rheumatol. 24, 1061–1065 (1997).
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Gladman DD, Urowitz MB. Mortality studies in SLE: how far can we improve survival of patients with SLE. Autoimmun. Rev. 3(6), 418–420 (2004).
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Diamond HS, Weiner M et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum. 25, 601–611 (1982).
   PubMed Web of Science ®Google Scholar
• Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum. 38, 274–283 (1995).
   PubMed Web of Science ®Google Scholar
• Doria A, Rinaldi S, Ermani M et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants. Rheumatology (Oxford)43, 1580–1586 (2004).
   PubMed Web of Science ®Google Scholar
• Testa MA, Simonson DC. Assessment of quality of life outcomes. N. Engl. J Med. 334, 835–840 (1996).
   PubMed Web of Science ®Google Scholar
• Thumboo J, Fong KY, Ng TP et al. Validation of the MOS SF-36 for quality of life assessment of patients with systemic lupus erythematosus in Singapore. J. Rheumatol. 26, 97–102 (1999).
   PubMed Web of Science ®Google Scholar
• Vu T, Escalante A. A comparison of the quality of life of patients with systemic lupus erythematosus with and without end stage renal disease. J. Rheumatol. 26, 2595–2601 (1999).
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Doria A, Salaffi F et al. Health-related quality of life in Italian patients with systemic lupus erythematosus. I. Relationship between physical and mental dimension and impact of age. Rheumatology (Oxford)43, 1574–1579 (2004).
   PubMed Web of Science ®Google Scholar
• Strand V, Aranow C, Cardiel MH et al. Improvement in health-related quality of life in SLE patients enrolled in a randomized clinical trial comparing LJP394 treatment with placebo. Lupus 12, 677–686 (2003).
   PubMed Web of Science ®Google Scholar
• Well-connected. Harvard Medical School (1999).
   Google Scholar
• Gilboe IM, Kvien TK, Husby G. Health status in systemic lupus erythematosus compared to rheumatoid arthritis and healthy controls. J. Rheumatol. 26, 1694–1700 (1999).
   PubMed Web of Science ®Google Scholar
• DaCosta D, Dobkin PL, Fitzcharles MA et al. Determinants of health status in fibromyalgia: a comparative study with systemic lupus erythematosus. J. Rheumatol. 27, 365–372 (2000).
   PubMed Web of Science ®Google Scholar
• Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome Measures in Clinical trials in Systemic Lupus Erythematosus. J. Rheumatol. 26, 490–497 (1999).
   PubMed Web of Science ®Google Scholar
• Saba J, Quinet RJ, Davis WE et al. Inverse correlation of each functional status scale of the SF-36 with degree of disease activity in systemic lupus erythematosus (m-SLAM). Joint Bone Spine 70, 348–351 (2003).
   PubMed Web of Science ®Google Scholar
• Sutcliffe N, Clarke AE, Levinton C, Frost C, Gordon C, Isenberg DA. Associates of health status in patients with systemic lupus erythematosus. J. Rheumatol. 26, 2352–2356 (1999).
   PubMed Web of Science ®Google Scholar
• Thumboo J, Fong KY, Chan SP et al. A prospective study of factors affecting quality of life in systemic lupus erythematosus. J. Rheumatol. 27(6), 1414–20 (2000).
   PubMed Web of Science ®Google Scholar
• Ware JE, Sherbourne CD. The MOS 36-Item Short Form Health Survey (SF-36): I. Conceptual framework and item selection. Med. Care 30, 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• Smolen J, Strand V, Cardiel M et al. Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J. Rheumatol. 26, 504–507 (1999).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Urowitz MB, Ong A, Gough J, MacKinnon A. A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). Lupus 5, 190–195 (1996).
   PubMed Web of Science ®Google Scholar
• Alonso J, Ferrer M, Gandek B et al. Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual. Life Res. 13, 283–298 (2004).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Urowitz MB, Fortin P et al. SLICC conferences on assessment of lupus flare and QOL measures in SLE. J. Rheumatol. 23, 1853–1855 (1995).
   Google Scholar
• Goldsmith C, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. J. Rheumatol. 20, 561–565 (1993).
   PubMed Web of Science ®Google Scholar
• Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr. Opin. Rheumatol. 14(2), 109–114 (2002).
   PubMed Web of Science ®Google Scholar
• Strand V, Scott DL, Emery P et al., for the Leflunomide Rheumatoid Arthritis Investigators Groups. Physical function and health-related quality of life: analysis of 2-year data from randomized, controlled studies of Leflunomide, Sulfasalazine, or Methotrexate in patients with active rheumatoid arthritis. J. Rheumatol. 32(4), 590–601 (2005).
   PubMed Web of Science ®Google Scholar
• Strand V. Longer term benefits of treating rheumatoid arthritis: assessment of radiographic damage and physical function over 2 years in clinical trials. Clin. Exp. Rheum. 22, S57–S64 (2004).
   PubMed Web of Science ®Google Scholar
• Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum. 45, 384–391 (2001).
   PubMed Web of Science ®Google Scholar
• Strand V, Kelman A. Outcome measures in randomized controlled trials in osteoarthritis. Curr. Rheumatol. Rep. 6, 20–30 (2004).
   PubMedGoogle Scholar
• Kujawski SC, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining meaningful improvement in SF-36 scale scores for treatment studies of early, active RA. Arthritis Rheum. 43(7), 1478–1487 (2000).
   PubMedGoogle Scholar
• Stucki G, Ewert T. How to assess the impact of arthritis on the individual patient: the WHO ICF. Ann. Rheum. Dis. 64(5), 664–668 (2005).
   PubMed Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J. Clin. Epidemiol. 47, 81–87 (1994).
   PubMed Web of Science ®Google Scholar
• Crawford B, Strand V. Improved health-related quality of life following sustained reductions in anti ds-DNA antibodies (dsDNA Ab) in patients with systemic lupus erythematosus (SLE) after treatment with LJP394. Abstract presented at International Society for Pharmacoeconomics and Research (2004).
   Google Scholar